These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15909775)

  • 21. Prevention of contrast-induced nephropathy: an overview.
    Ellis JH; Cohan RH
    Radiol Clin North Am; 2009 Sep; 47(5):801-11, v. PubMed ID: 19744595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contrast associated nephropathy in the elderly.
    Carrillo-Alvira F; Rivera-Bermúdez CG; Jiménez-Velázquez IZ; Ramos-Romey C; González-Concepción JJ
    Bol Asoc Med P R; 2008; 100(3):25-7. PubMed ID: 19227712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contrast-induced nephropathy remains a serious complication of PCI.
    Mehran R
    J Interv Cardiol; 2007 Jun; 20(3):236-40. PubMed ID: 17524117
    [No Abstract]   [Full Text] [Related]  

  • 24. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best?
    Shalansky SJ; Vu T; Pate GE; Levin A; Humphries KH; Webb JG
    Pharmacotherapy; 2005 Aug; 25(8):1095-103. PubMed ID: 16207100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy.
    Trivedi H; Daram S; Szabo A; Bartorelli AL; Marenzi G
    Am J Med; 2009 Sep; 122(9):874.e9-15. PubMed ID: 19699385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-acetylcysteine in the prevention of contrast-induced nephropathy.
    Fishbane S
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):281-7. PubMed ID: 18003766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration.
    Shalansky SJ; Pate GE; Levin A; Webb JG
    Heart; 2005 Aug; 91(8):997-9. PubMed ID: 16020580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical practice. Preventing nephropathy induced by contrast medium.
    Barrett BJ; Parfrey PS
    N Engl J Med; 2006 Jan; 354(4):379-86. PubMed ID: 16436769
    [No Abstract]   [Full Text] [Related]  

  • 29. N-acetylcysteine and/or theophylline as a preventive measure for contrast agent induced nephropathy: we should use better markers for detection of renal function.
    Schultz MJ
    Radiology; 2007 Dec; 245(3):918-9; author reply 918-9. PubMed ID: 18024462
    [No Abstract]   [Full Text] [Related]  

  • 30. N-acetylcysteine attenuates iodine contrast agent-induced nephropathy in 5/6-nephrectomized rats.
    Sochman J; Peregrin JH; Bürgelová M; Kopkan L; Kramer HJ; Cervenka L
    Kidney Blood Press Res; 2010; 33(2):149-56. PubMed ID: 20502036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of N-Acetylcysteine to Prevent Contrast-Induced Nephropathy: A Meta-analysis.
    Loomba RS; Shah PH; Aggarwal S; Arora RR
    Am J Ther; 2016; 23(1):e172-83. PubMed ID: 23982694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy?
    Gonzales DA; Star RA; Kern SJ; Natanson C; Danner RL
    Ann Intern Med; 2008 Aug; 149(3):213-4; author reply 215-6. PubMed ID: 18678852
    [No Abstract]   [Full Text] [Related]  

  • 33. Contrast agent nephropathy.
    Nicol P; Axelson C
    Eur Heart J; 2004 Aug; 25(15):1369; discussion 1369-70. PubMed ID: 15288173
    [No Abstract]   [Full Text] [Related]  

  • 34. Is there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy?
    Trivedi H
    Ann Intern Med; 2008 Aug; 149(3):213; author reply 215-6. PubMed ID: 18678853
    [No Abstract]   [Full Text] [Related]  

  • 35. Is there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy?
    Berwanger O
    Ann Intern Med; 2008 Aug; 149(3):215; author reply 215-6. PubMed ID: 18678855
    [No Abstract]   [Full Text] [Related]  

  • 36. Is there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy?
    Ferrante G; Locca D; Barlis P
    Ann Intern Med; 2008 Aug; 149(3):214-5; author reply 215-6. PubMed ID: 18678854
    [No Abstract]   [Full Text] [Related]  

  • 37. [Can the nephroprotective effect of N-acetylcysteine be optimized?].
    Barrios V; Escobar C; Echarri R
    Rev Esp Cardiol; 2010 Apr; 63(4):501-2. PubMed ID: 20334824
    [No Abstract]   [Full Text] [Related]  

  • 38. N-acetylcysteine in preventing contrast-induced nephropathy. To give, or not to give: that is the question.
    Mehran R; Caixeta A
    Rev Esp Cardiol; 2010 Jan; 63(1):9-11. PubMed ID: 20089220
    [No Abstract]   [Full Text] [Related]  

  • 39. [New usage for an old drug: acetylcysteine for contrast-induced nephropathy].
    Asher I; Hammerman A; Sthoeger Z
    Harefuah; 2005 Sep; 144(9):642-6; 675. PubMed ID: 16218537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of N-acetylcysteine on renal hemodynamics in contrast media-induced nephropathy.
    Krzossok S; Braun C; Weiss E; Hoeger S; Schnuelle P; Benck U; Birck R; Krämer BK; Göttmann U
    Kidney Blood Press Res; 2011; 34(2):125-34. PubMed ID: 21335974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.